ClinicalTrials.gg
CompletedNCT05745883Updated Apr 22, 2026

Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia

A Phase 1 interventional study of DISC-0974 and Placebo in Chronic Kidney Diseases and Anemia of Chronic Kidney Disease, sponsored by Disc Medicine, Inc. Completed at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Disc Medicine, Inc · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 170 open to participants now, 218 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.

Enrollment
460th of 819
55 · median 72
Started
2023
with 46 others
Phase 1
93 of 988
15 open now
Registered
792nd of 988
by date

Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 460th largest by enrollment of the 819 interventional ones that give a count, is one of 47 that started in 2023, is one of 93 in phase 1, and was the 792nd registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

170 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:

165 more — sign in →

All 170 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 988 studies in Renal Insufficiency, Chronic with a site in United States, or all of them as a file.
02

Study summary

This Phase 1b study of DISC-0974 will assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of DISC-0974 in adult participants with Non-Dialysis Dependent Chronic Kidney Disease and Anemia.

03

Conditions studied

  • Chronic Kidney Diseases
  • Anemia of Chronic Kidney Disease

Keywords

  • Chronic Kidney Disease
  • Anemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥18 years of age at the time of signing .
  2. Non-dialysis-dependent chronic kidney disease, Stages 2-5, defined as \<90 mL/min/1.73 m2 using the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula
  3. \<11.0 g/dL
  4. Serum ferritin ≥50 μg/L at screening
  5. Transferrin saturation ≤35%
  6. and ALT \<2× (ULN) at screening
  7. Total and direct \<ULN at screening
  8. If female, then EITHER , defined as at least 12 months of natural, spontaneous amenorrhea and serum follicle-stimulating hormone >40 mIU/mL at screening, or at least 6 weeks following surgical menopause (bilateral oophorectomy or hysterectomy); OR agreeable to use of highly effective (listed below) on Day 1 (or earlier) for at least 8 weeks after the last dose of study drug:

    • Stable hormonal contraceptive (≥3 months) in conjunction with a barrier method (eg, condom [male or female] or diaphragm)
    • Intrauterine device in place for at least 3 months
    • Tubal ligation or single male partner with vasectomy in conjunction with a barrier method (eg, condom [male or female] or diaphragm)
  9. If male with female sexual partner(s) of , agrees to use one of the following acceptable methods of contraception during the study and for at least 8 weeks after the last study drug dose:

    1. Stable hormonal contraceptive (≥3 months; female partner) in conjunction with a barrier method (eg, condom or diaphragm [female partner])
    2. Intrauterine device in place for at least 3 months (female partner)
    3. Surgically sterile hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner) in conjunction with a barrier method (eg, condom [male or female] or diaphragm)
    4. Confirmed successful vasectomy in conjunction with a barrier method (eg, condom [male or female] or diaphragm)
  10. Able to understand and provide written informed consent
  11. Able to comply with all study procedures

Exclusion criteria

Exclusion Criteria:

  1. Treatment within 2 days prior to screening with oral iron or iron-containing supplements. Participants may be considered for the study if they undergo a 2-day prior to signing the form (ICF) and screening for oral iron or iron-containing supplements. Between screening and 2 days prior to baseline visit, participants may continue oral iron or iron-containing supplements at the discretion of the Investigator, but any study-related lab draws will require a 48-hour washout from oral iron
  2. Treatment within 30 days prior to screening with one of the following anemia treatments: blood transfusion, ESAs, or IV iron. Participants may be considered for the study if they undergo a 30-day washout period prior to signing the ICF and screening for erythropoietin-stimulating agents or IV iron
  3. Acute dialysis or acute kidney injury within 12 weeks prior to screening or expected need to start dialysis within 24 weeks of screening
  4. Hospitalization for a CV, renal, or cardiorenal condition within 30 days prior to screening
  5. Positive direct antiglobulin test with reactive eluate at screening or active hemolytic anemia. This test can be performed prior to other screening procedures after the participant is consented for the prescreening testing
  6. History of hereditary hemochromatosis
  7. History of hemoglobinopathy or intrinsic red blood cell defect associated with anemia
  8. History of total splenectomy
  9. Hematopoietic stem cell or solid organ transplant within the past 10 years
  10. Medical history of anemia from B12 or folate deficiency, infection, or bleeding in the 3 months prior to screening
  11. Stroke, myocardial infarction, deep venous thrombosis, pulmonary or arterial embolism within 6 months prior to screening
  12. If female, pregnant or breastfeeding
  13. Any major surgery within 8 weeks before screening or incomplete recovery from any previous surgery
  14. History of within the last 3 years. The following history/concurrent conditions are allowed: basal or squamous cell carcinoma skin cancer, carcinoma in situ of the cervix, carcinoma in situ of the breast, histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, [TNM] clinical staging system). A history of completed treatment (medical or surgical) of Stage 1-2 cancers may be permitted with prior Sponsor agreement
  15. Participation in any other clinical protocol or study that involves administration of experimental therapy and/or therapeutic devices within 30 days of screening
  16. A history or known allergic reaction to any investigational product or history of anaphylaxis to any food or drug
  17. History of anti-drug antibody formation
  18. History of inadequately controlled heart disease ( Classification 3 or 4) and/or have a known \<35%
  19. Uncontrolled fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement, despite appropriate treatment)
  20. positive, active , or active
  21. Uncontrolled diabetes mellitus (defined as diabetes mellitus requiring initiation of insulin therapy within 3 months of screening)
  22. Significant medical condition, laboratory abnormality, or psychiatric condition that would prevent the patient from participating in the study
  23. Any condition or concomitant medication that would confound the ability to interpret data from the study
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Phase 1b Single Dose

    Single dose of DISC-0974

  • Placebo comparator
    Single Dose of Placebo

    Single dose of placebo

    Drug: Placebo

  • Experimental
    Phase 1b Multiple Doses

    Multiple doses of DISC-0974

    Drug: DISC-0974

  • Placebo comparator
    Multiple Doses of Placebo

    Multiple doses of placebo

    Drug: Placebo

Interventions

  • DISC-0974 is administered subcutaneously

  • DrugPlacebo

    Placebo is administered subcutaneously

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events

    Time frame: up to 145 days

  2. Incidence of clinically abnormal vital signs

    Time frame: up to 145 days

  3. Incidence of abnormal laboratory test results

    Time frame: up to 145 days

  4. Incidence of clinically abnormal physical exam

    Time frame: up to 145 days

  5. Incidence of clinically abnormal electrocardiograms

    Time frame: up to 145 days

Secondary outcomes

  1. Change from baseline in concentration of iron laboratory parameter

    Time frame: up to 145 days

  2. Change from baseline in concentration of hematologic laboratory parameters

    Time frame: up to 145 days

  3. Cmax-Maximum drug concentration measured in plasma

    Time frame: up to 145 days

  4. Tmax-Time of maximum drug concentration

    Time frame: up to 145 days

  5. AUC-Area under the drug concentration time curve

    Time frame: up to 145 days

  6. T½ - Elimination half life of the drug

    Time frame: up to 145 days

  7. CL/F-Apparent drug clearance (only for single-dose portion)

    Time frame: up to 57 days

  8. Vz/F; Vss/F -Apparent volume of distribution of the drug (only for single-dose portion)

    Time frame: up to 57 days

07

Study locations

13 sites
  • UCLA Clinical and Translational Research
    Los Angeles, California 90095, United States
  • US Renal Care Inc.
    Lone Tree, Colorado 80124, United States
  • Accel Research
    DeLand, Florida 32720, United States
  • Total Research Group
    Miami, Florida 33126, United States
  • Flourish Research
    Winter Park, Florida 32789, United States
  • Nephrology and Hypertension Specialists, PC-Dalton
    Dalton, Georgia 30720, United States
  • CARE Institute - Boise Kidney
    Boise, Idaho 83706, United States
  • Center for Advanced Kidney Research PLC
    Saint Clair Shores, Michigan 48081, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Centricity Research
    Columbus, Ohio 43213, United States
  • Clinical Advancement Center, PLLC
    San Antonio, Texas 78212, United States
  • Endeavor Clinical Trials
    San Antonio, Texas 78240, United States
  • Washington Nephrology Associates, LLP
    Alexandria, Virginia 22304, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Oct 2025, 30 months.

Of 77 industry-sponsored phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 30 months is above that.

Counting every sponsor, half of 109 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2023
First posted
Feb 27, 2023
StartActual
Apr 4, 2023
Primary completionActual
Oct 9, 2025
CompletionActual
Jan 16, 2026
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05745883
Lead sponsor
Disc Medicine, Inc
Responsible party
Sponsor
First posted
Feb 27, 2023
Start date
Apr 4, 2023
Primary completion
Oct 9, 2025
Completion
Jan 16, 2026
Last update
Apr 22, 2026

Study contacts

Will Savage, MD PhD
study director · Disc Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selcodebart

Start the discussion